Novavax (NVAX) Gross Profit (2011 - 2026)
Novavax (NVAX) posted quarterly Gross Profit of $108.8 million for Q1 2026, down 83.32% year-over-year from $652.5 million in Q1 2025, and down 12.97% quarter-over-quarter from $125.0 million in Q4 2025.
Novavax (NVAX) Gross Profit (2011 - 2026) Analysis & Trends
Novavax's Gross Profit history runs 11 years deep, the most recent figure standing at $108.8 million for Q1 2026.
- In Q1 2026, Gross Profit fell 83.32% year-over-year to $108.8 million; the TTM figure through Mar 2026 stood at $442.5 million (down 59.68% YoY), while the FY2025 annual figure was $1.1 billion, up 119.1% from the prior year.
- Gross Profit for Q1 2026 stood at $108.8 million, down from $125.0 million in the prior quarter.
- The five-year high for Gross Profit was $688.8 million in Q1 2022, with the low at -$85.2 million in Q2 2022.
- The 5-year median for Gross Profit is $125.0 million (2025), against an average of $193.7 million.
- The sharpest annual moves came in 2022 and 2025: Gross Profit tumbled 128.57% in 2022, then jumped 1783.45% in 2025.
- Novavax's Gross Profit stood at $175.6 million in 2022, then retreated by 22.36% to $136.4 million in 2023, then slumped by 62.13% to $51.6 million in 2024, then jumped by 142.12% to $125.0 million in 2025, then fell by 12.97% to $108.8 million in 2026.
- Business Quant data shows NVAX's Gross Profit at $108.8 million in Q1 2026, $125.0 million in Q4 2025, and $48.9 million in Q3 2025.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|